Orbis Medicines Targets Oral Biologics Opportunity at Anglonordic Conference

According to a recent LinkedIn post from Orbis Medicines, the company plans to participate in the Anglonordic Life Science Conference in London on April 23, where its CEO is expected to join discussions with European investment firms. The post highlights investor interest in oral biologics as a potential alternative to injectable biologics, emphasizing both market share capture and patient population expansion via more convenient drug delivery.

The LinkedIn post suggests that Orbis Medicines is positioning itself as a specialist in oral macrocycle drug discovery, combining high-throughput synthesis, screening technologies, and AI-based design to improve oral bioavailability. For investors, this focus may indicate a bid to secure partnering opportunities and future licensing revenue in the biologics space, while conference visibility and direct outreach to investors could support future funding or strategic collaboration prospects.